Teaming

Teaming collaborations between diverse innovators are encouraged to help advance the development of a single-administration pandemic influenza A(H5N1) vaccine. Entrants interested in forming teams can fill out the teaming form to share a participant profile and connect with potential collaborators. Entrants are also invited to register for the September 29 Proposers’ Day to connect with other prospective entrants and potential partners.

Entrant profiles will be available on this page for those looking to connect with others in the field. The page will be updated regularly throughout the open submissions period.

Fill out the teaming form

 

Teams

Select All That Apply

Boost Biopharma, Inc.

Boston, MA

My team specializes in

Antigen development

Summary of core technology or service

Boost Biopharma is a clinical-stage company that creates exceptional protein subunit antigens. We are interested in partnering on adjuvants and/or delivery technologies that have the potential to further improve our vaccines' single-dose performance.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSNOVEL DELIVERY SYSTEMS

Contact

Steve Gold

Role

CEO

Contact email address

steve@boostbiopharma.com

Website

www.boostbiopharma.com

Vaccine Formulation Institute

Switzerland

My team specializes in

Adjuvants

Summary of core technology or service

VFI develops and supplies GMP-grade, open-access vaccine adjuvants based on emulsion and liposome technologies, combined with formulation expertise and technical, preclinical, regulatory and quality support for vaccine development.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

Maria Lawrenz

Role

Operations Director

Contact email address

maria.lawrenz@vformulation.org

Website

www.vaccineformulationinstitute.org

Nebraska Center for Virology

Lincoln, NE

My team specializes in

Antigen development

Summary of core technology or service

We integrate a systems approach that combines bioinformatics, phylogenetics, immunology, and molecular biology to design rapid, durable, cross-protective vaccines.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

NOVEL DELIVERY SYSTEMSADJUVANTS

Contact

Eric Weaver

Role

Director

Contact email address

eweaver2@unl.edu

Website

virology.unl.edu

OmniPulse Biosciences, Inc.

Cambridge, MA

My team specializes in

Novel delivery systems

Summary of core technology or service

We have a highly scalable, pulsatile-release injectable platform. A single injection delivers multiple, time-released doses — eliminating the need for follow-up boosters. Co-formulation is not required. We can manufacture clinical product in-house.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENT

Contact

Bob Farra

Role

CTO

Contact email address

rfarra@omnipulsebio.com

Website

www.omnipulsebio.com

Advanced BioScience Laboratories (ABL, Inc.)

Rockville, MD

My team specializes in

Other

Summary of core technology or service

cGMP production and testing of products from preclinical, clinical, to commercial phase in both adherent and suspension systems. Our experience includes multiple modalities including live virus, viral vectors, subunits, nanoparticles, and others.

The earliest stage My team is interested in submitting to

STAGE 1: NONCLINICAL PROOF OF CONCEPT

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENTNOVEL DELIVERY SYSTEMSADJUVANTS

Contact

Timothy R Fouts

Role

CSO

Contact email address

timothy.fouts@ablinc.com

Website

www.ablinc.com

University of Maryland, Baltimore

Baltimore, Maryland, USA

My team specializes in

Antigen development

Summary of core technology or service

My lab has capacity to design, express and purify recombinant proteins in mammalian cells. We have extensive experience with influenza hemagglutinin (HA), including avian H5. We currently have an inventory of over 30 H5 strains, spanning all clades.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSNOVEL DELIVERY SYSTEMS

Contact

Lynda Coughlan

Role

Associate Professor and Principal Investigator

Contact email address

lcoughlan@som.umaryland.edu

Website

www.medschool.umaryland.edu

HDT Bio

Seattle, WA

My team specializes in

AdjuvantsNovel delivery systems

Summary of core technology or service

HDT Bio's LION™ technology is a GMP and clinically validated delivery platform that enables co-delivery of adjuvants to simultaneously target orthogonal pathways, including RIG-I and multiple TLRs (TLR3/4/7/8)

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

Amit Khandhar

Role

Director, Formulations

Contact email address

amit.khandhar@hdt.bio

Website

www.hdt.bio

American Type Culture Collection

Manassas, VA

My team specializes in

OtherAntigen developmentNovel delivery systems

Summary of core technology or service

Providing biological resource expertise, characterized virus stocks, custom reference materials, cGMP-compliant biorepository services, and production capabilities that help innovators de-risk, validate, and accelerate pandemic countermeasures.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENTNOVEL DELIVERY SYSTEMS

Contact

Eldar Imanverdi

Role

Senior Director, Business Development

Contact email address

eimanverdi@atcc.org

Website

www.atcc.org

Uvax Bio, LLC

Dover, Delaware, U.S.A.

My team specializes in

Antigen developmentNovel delivery systems

Summary of core technology or service

Multilayered, stable protein nanoparticle scaffold displaying multimeric array of PF stabilized H5N1 HA trimers

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENT

Contact

Kevin O'Neill

Role

Chief Executive Officer

Contact email address

kevin.oneill@uvaxbio.com

Website

www.uvaxbio.com

TollereBio

USA

My team specializes in

Adjuvants

Summary of core technology or service

TollereBio's BECC adjuvant technology offers best in class, rationally designed, fully synthetic TLR4 agonist adjuvants backed by pre-clinical data.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENTEXCIPIENTSNOVEL DELIVERY SYSTEMSADJUVANTS

Contact

Hans Lien

Role

COO

Contact email address

hans.lien@tollerebio.com

Website

www.tollerebio.com

LTS Lohmann

Germany, US

My team specializes in

Novel delivery systems

Summary of core technology or service

LTS’s proprietary AccuTip dissolvable microneedle patch combines novel vaccine delivery, manufacturing-ready scale-up, and deep experience across a variety of actives—enabling rapid adaptation to virtually any vaccine for the Single Shield Prize.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

May Pidding

Role

Global Strategic Product Management

Contact email address

may.pidding@ltslohmann.com

Website

www.ltslohmann.com

Texas Biomedical Research Institute

San Antonio, Texas

My team specializes in

Other

Summary of core technology or service

Our team can provide integrated preclinical evaluation of vaccine candidates, from immunization to challenge and transmission studies through immunological, virological, and pathological characterization using mice, guinea pigs, ferrets, and NHP.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENTNOVEL DELIVERY SYSTEMS

Contact

Luis Martinez-Sobrido

Role

Principal Investigator

Contact email address

lmartinez@txbiomed.org

Website

www.txbiomed.org

Codagenix Inc.

New York, USA

My team specializes in

Antigen development

Summary of core technology or service

We discover and develop live virus vaccines for A/H5N1 that can be inactivated and/or adjuvanted with novel agents to be responsive to this Prize and are looking for partners including biomarker partners to demonstrate safety and efficacy

The earliest stage My team is interested in submitting to

STAGE 1: NONCLINICAL PROOF OF CONCEPT

We are interested in partnerships with entities specializing in

ADJUVANTSNOVEL DELIVERY SYSTEMS

Contact

Jeffrey Fu

Role

Chief Business Officer

Contact email address

jfu@codagenix.com

Website

codagenix.com

VisMederi America Corp.

Cleveland, OH

My team specializes in

Other

Summary of core technology or service

Pre-clinical services to include immunogenicity and efficacy evaluations Bioanalytical support using validated influenza assays for pre-clinical and clinical studies

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENTNOVEL DELIVERY SYSTEMSADJUVANTS

Contact

Brian Price

Role

President

Contact email address

brian.price@vismederiamerica.com

Website

www.vismederi.com

Photosynthetic B.V.

Amsterdam, The Netherlands

My team specializes in

Novel delivery systemsOther

Summary of core technology or service

Photosynthetic develops a high-resolution volumetric printing platform for rapid microfabrication. The technology enables complex polymer microstructures, including microneedle arrays and other vaccine-delivery components, with micron-scale precision

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

EXCIPIENTSANTIGEN DEVELOPMENTADJUVANTS

Contact

Magdalena Kurzyp

Role

CBO

Contact email address

magdalena@photosynthetic.nl

Website

photosynthetic.nl

Vaxine Inc

Colorado

My team specializes in

AdjuvantsAntigen developmentNovel delivery systems

Summary of core technology or service

Vaxine specialises in development of new adjuvants targetting DC-SIGN (Advax delta inulin adjuvant), TLR9 (CpG55.2) as well as having candidate compounds targeting TLR2, TLR4, TLR7/8 and NOD2. It also has expertise in antigen design and delivery.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

NOVEL DELIVERY SYSTEMSANTIGEN DEVELOPMENT

Contact

Nikolai Petrovsky

Role

Research Director

Contact email address

nikolai.petrovsky@vaxine.net

Website

vaxine.net

Texas Children's Ctr for Vaccine Development, Baylor College Med

Houston, TX, USA

My team specializes in

Antigen developmentOtherAdjuvants

Summary of core technology or service

We develop recombinant protein vaccines against viruses, with experience in technology transfer, QA/RA systems, and IND submissions to the US FDA supporting translation from discovery through clinical readiness.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENTEXCIPIENTSNOVEL DELIVERY SYSTEMS

Contact

Ulrich Strych

Role

Director for Strategic Initiatives and Program Development

Contact email address

strych@bcm.edu

Website

www.texaschildrens.org

Vaxxas Pty Ltd

Brisbane, Queensland, Australia

My team specializes in

Novel delivery systems

Summary of core technology or service

The high-density microarray patch (HD-MAP) is a needle-free vaccine delivery platform for skin-based vaccine delivery. Potential benefits: enhanced immune response, antigen dose-sparing, improved thermostability, and simplified administration.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

Elouise Comber

Role

Business Development

Contact email address

ecomber@vaxxas.com

Website

www.vaxxas.com

DEKA

Manchester, NH

My team specializes in

Novel delivery systems

Summary of core technology or service

Self-administrable, intradermal vaccine applicator

The earliest stage My team is interested in submitting to

STAGE 1: NONCLINICAL PROOF OF CONCEPT

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

Fareena

Role

VP - Strategy & Commercialization

Contact email address

fareena@dekaresearch.com

Website

www.dekaresearch.com

Apply now: September 29 Proposers’ Day

Register